Category: Latest News
-
Dyne Therapeutics Shares Rise 3.6% After FDA Grants Breakthrough Therapy Status
Dyne Therapeutics Inc (NASDAQ:DYN) stock climbed 3.6% following the announcement that the U.S. Food and Drug Administration (FDA) awarded Breakthrough Therapy Designation to its DYNE-251 treatment targeting Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping. This designation was granted based on promising data from Dyne’s ongoing DELIVER clinical trial. The breakthrough status offers…
-
D-Wave Quantum Shares Climb 3.7% After Launch of Quantum AI Toolkit
Shares of D-Wave Quantum Inc. (NYSE:QBTS) increased by 3.7% following the company’s announcement of a new suite of tools designed to help developers explore and accelerate advancements in quantum artificial intelligence (AI) and machine learning (ML). The pioneer in quantum computing unveiled an open-source quantum AI toolkit and demonstration that allows developers to seamlessly incorporate…
-
Atlasclear Stock Rockets 50% Following $500K Debenture Investment
Shares of Atlasclear Holdings Inc (AMEX:ATCH) surged by 50% after the company announced a $500,000 debenture investment from Sixth Borough Capital LP, a firm led by Dawson James CEO Robert D. Keyser, Jr. This infusion aligns with Atlasclear’s growth strategy, focused on boosting revenues through expanding broker relationships, ramping up retail operations, and enhancing investment…
-
Hillevax Shares Gain on Acquisition Deal with XOMA Royalty
Shares of Hillevax Inc (NASDAQ:HLVX) climbed 2.9% after the company revealed it had entered into a definitive merger agreement with XOMA Royalty Corporation (NASDAQ:XOMA), marking the latest in a series of acquisitions by XOMA in the biotech space. According to the agreement, XOMA Royalty will acquire all outstanding shares of Hillevax for $1.95 in cash…
-
LAVA Therapeutics Shares Climb on Buyout Deal with XOMA Royalty
LAVA Therapeutics N.V. (NASDAQ:LVTX) saw its stock rise 4.2% following news of a share purchase agreement with XOMA Royalty Corporation (NASDAQ:XOMA), under which XOMA will acquire LAVA in a cash and milestone-based deal. As outlined in the terms, shareholders of LAVA will receive between $1.16 and $1.24 per share in cash, along with a non-transferable…
-
Replimune Shares Slide as FDA Dispute Over Cancer Drug Approval Comes to Light
Shares of Replimune Group Inc. (NASDAQ:REPL) plunged 36% in premarket trading after a report revealed new details about the internal dynamics behind the FDA’s rejection of its skin cancer treatment, RP1. The report, published by STAT, suggested that a high-ranking FDA cancer drug official stepped in late during the review process and influenced the decision—despite…
-
Baidu and Lyft Shares Rise on Plans to Launch Robotaxi Service in Europe
Stocks of Baidu (NASDAQ:BIDU) and Lyft (NASDAQ:LYFT) traded higher on Monday following news of a new international collaboration. The Chinese tech powerhouse announced a partnership with Lyft to introduce its autonomous vehicles to the European market, marking a significant step in both companies’ driverless mobility ambitions. Baidu’s shares climbed nearly 3% in premarket trading, while…
-
Verb Technology Stock Skyrockets Following $558M Deal to Launch TON Strategy Firm
Shares of Verb Technology Company (NASDAQ:VERB) soared 90% after the company unveiled a major private placement to fund a strategic transformation. The Las Vegas-based firm is raising approximately $558 million through a PIPE transaction aimed at creating the first publicly traded company focused on TON Treasury Strategy, in collaboration with Kingsway Capital. The transaction includes…
-
Krystal Biotech Shares Rise After Q2 Earnings, Revenue Beat Expectations
Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) gained 3.8% after the company released second-quarter financial results that topped Wall Street estimates, thanks to robust sales of its lead therapy, VYJUVEK, used to treat dystrophic epidermolysis bullosa (DEB). The biotech firm posted adjusted earnings of $1.29 per share, beating analyst expectations of $1.22. Revenue came in at…
-
Lindblad Expeditions Jumps After Q2 Revenue Tops Expectations
Shares of Lindblad Expeditions Holdings, Inc. (NASDAQ:LIND) surged 10.8% in premarket trading following the release of second-quarter earnings that beat Wall Street forecasts. The adventure travel and expedition cruise company benefited from stronger pricing power and improved occupancy rates. For the quarter, Lindblad posted a net loss of $0.18 per share, narrower than the $0.28…